185,550 Shares in Krystal Biotech, Inc. $KRYS Bought by T. Rowe Price Investment Management Inc.

Key Points

• T. Rowe Price Investment Management Inc. acquired 185,550 shares of Krystal Biotech, Inc. for approximately $33.5 million, representing about 0.64% ownership in the company.
• Multiple hedge funds, including Brooklyn Investment Group and Fifth Third Bancorp, significantly increased their stakes in Krystal Biotech during the first quarter.
• Krystal Biotech currently has a consensus rating of "Buy" from analysts and an average target price of $210.38, despite recent adjustments to individual target prices.

T. Rowe Price Investment Management Inc. purchased a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 185,550 shares of the company's stock, valued at approximately $33,455,000. T. Rowe Price Investment Management Inc. owned about 0.64% of Krystal Biotech as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in KRYS. Nuveen LLC acquired a new position in shares of Krystal Biotech in the 1st quarter valued at $42,223,000. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 65.2% in the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company's stock valued at $56,144,000 after purchasing an additional 141,400 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 50,249.4% in the 1st quarter. GAMMA Investing LLC now owns 121,342 shares of the company's stock valued at $21,878,000 after purchasing an additional 121,101 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Krystal Biotech by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after purchasing an additional 71,200 shares during the last quarter. Finally, Integral Health Asset Management LLC acquired a new position in shares of Krystal Biotech in the 4th quarter valued at $8,616,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of Krystal Biotech stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares of the company's stock, valued at $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 49,800 shares of company stock worth $7,487,943. Insiders own 13.70% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on KRYS. Chardan Capital decreased their price target on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a report on Friday, August 22nd. Citigroup restated a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Guggenheim reduced their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Bank of America reduced their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. Finally, HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $210.38.

Krystal Biotech Price Performance

Krystal Biotech stock traded down $1.54 during midday trading on Friday, hitting $149.23. 55,699 shares of the stock were exchanged, compared to its average volume of 327,146. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $207.84. The firm has a market cap of $4.32 billion, a P/E ratio of 30.20 and a beta of 0.70. The company has a 50 day moving average price of $145.52 and a two-hundred day moving average price of $154.32.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).